- Home
- OUST vs SPRY Comparison
OUST vs SPRY Comparison
Compare OUST & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OUST | SPRY |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | OUST | SPRY |
|---|---|---|
| Price | $23.32 | $11.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $34.80 | $31.25 |
| AVG Volume (30 Days) | ★ 1.6M | 1.6M |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $137,298,000.00 | ★ $142,772,000.00 |
| Revenue This Year | $35.72 | N/A |
| Revenue Next Year | $35.65 | $127.81 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 30.20 | ★ 5459.66 |
| 52 Week Low | $6.34 | $6.66 |
| 52 Week High | $41.65 | $18.90 |
Technical Indicators
Market Signals| Indicator | OUST | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 50.42 | 62.10 |
| Support Level | $21.04 | $10.94 |
| Resistance Level | $23.61 | $11.99 |
| Average True Range (ATR) | 1.36 | 0.65 |
| MACD | 0.10 | 0.07 |
| Stochastic Oscillator | 46.49 | 78.96 |
Price Performance
Historical ComparisonAbout OUST Ouster Inc.
Ouster Inc is a provider of lidar sensors for the automotive, industrial, robotics, and smart infrastructure industries. Ouster's products include high-resolution scanning and solid-state digital lidar sensors, Velodyne Lidar sensors, and software solutions. The company operates in the Americas, Asia and Pacific, Europe, Middle East, and Africa regions. It derives maximum revenue from Americas.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.